Rapamune Whistleblower Suit Gets Jolt From Government Intervention
This article was originally published in The Pink Sheet Daily
The Department of Justice has intervened in a qui tam suit alleging Wyeth promoted the immunosuppressant for off-label uses and offered kickbacks to providers. Settlement now seems more likely.
You may also be interested in...
Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.